ClinicalTrials.gg
CompletedNCT05425056ACCESS2Updated Oct 6, 2026Results posted

A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

A Phase 3 interventional study of Sirolimus in Complication of Renal Dialysis, End Stage Renal Disease and End Stage Kidney Disease, sponsored by Vascular Therapies, Inc.. Completed at 22 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Vascular Therapies, Inc. · Phase 3, Interventional, and Prevention

Updated Oct 6, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing sirolimus in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Sirolimus · Kidney Failure, Chronic.

Enrollment
4th of 12
136 · median 80
Started
2022
the only one that year
Phase 3
3 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
2 of 12
Vascular Therapies, Inc.

Among the 12 studies testing sirolimus in Kidney Failure, Chronic, this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 3, and was the 12th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies testing sirolimus in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing sirolimus in Kidney Failure, Chronic as a file.
02

Study summary

The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.

Read the detailed description

This is a Phase 3, multicenter, randomized, single-blind, controlled, study designed to evaluate the efficacy and safety of the use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects who are on hemodialysis and are undergoing surgical creation of an AV fistula in comparison to subjects who do not receive the implant.

Subjects of either gender, who are at least 65 years of age, undergoing hemodialysis, and require a new single stage radiocephalic end to side fistula will be eligible to participate in this study. Subjects who meet eligibility criteria and undergo successful AV fistula creation will be eligible for enrollment. The study plans to enroll approximately 120 subjects, randomized in a 1:1 ratio. Enrolled subjects will be followed for a period of one year from the time of their index surgical procedure.

03

Conditions studied

  • Complication of Renal Dialysis
  • End Stage Renal Disease
  • End Stage Kidney Disease
  • ESRD
  • Chronic Kidney Failure
  • Complication of Hemodialysis
  • Vascular Access Complication
  • Arteriovenous Fistula

Keywords

  • Arteriovenous Fistula
  • Hemodialysis vascular access
  • Dialysis fistula
  • Dialysis access
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 years or older
  • Currently on hemodialysis for ≤12 months
  • Successful creation of a single stage radiocephalic end to side fistula

Exclusion criteria

Exclusion Criteria:

  • Prior AV access created on the limb where the fistula surgery is planned
  • Planned start of peritoneal dialysis within 6 months of randomization
  • Known to the following: sirolimus, beef or bovine collagen
  • Known to be positive
  • Prisoner, mentally incompetent, and/or current alcohol or drug abuser
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Subjects randomized to the treatment arm will undergo AV fistula surgery and will receive the Sirolimus eluting Collagen Implant (SeCI).

    Drug: Sirolimus

  • No intervention
    Control Arm

    Subjects randomized to the control arm will undergo AV fistula surgery alone and will not receive an implant.

Interventions

  • SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.

    Also known as: Sirolimus-eluting Collagen Implant, SeCI, Sirogen

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Fistula Maturation (FM)

    Clinical Fistula Maturation (FM) is defined as a fistula that can be cannulated with 2-needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of 300 mL/min (unless the prescribed Qb is \<300 mL/min) performed during any continuous 30 day period that commences no later than 180 days after randomization. FM will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The KM proportions (and associated 95% CIs) for FM for the two groups will be evaluated on day 210.

    Time frame: 6 Months

Secondary outcomes

  1. Fistula Suitability for Dialysis at 12 Months (FSD12)

    Fistula Suitability for Dialysis at 12 months (FSD12) defined as a fistula that can be used for dialysis using 2 needles for at least 75% of the dialysis sessions performed during a 30 day period that commences on day 330.

    Time frame: 1 year

  2. Percentage of Participants With Secondary Patency at 12 Months

    Secondary Patency (SP) defined as the interval from the time of randomization until access abandonment. SP will be summarized as the cumulative proportion of abandoned AVF by plotting the (inverted SP) Kaplan-Meier (KM) curves for each treatment group and estimating the KM proportions (and associated 95% CIs) of AVF that have maintained SP by day 360 or end of study visit (whichever is later).

    Time frame: 12 Months

  3. Percentage of Participants With First Dialysis (TTFD) at 12 Months

    Time To First Dialysis (TTFD) defined as the interval from the time of randomization to the first of three consecutive dialysis sessions using 2 needles with a mean Qb of ≥300 mL/min (unless the prescribed Qb is \<300 mL/min). TTFD will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for each group (treatment and controls) and estimating the KM proportions (and associated 95% CIs) achieving first dialysis by day 360. TTFD will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The TTFD proportions (and associated 95% CIs) for TTFD for the two groups will be evaluated on day 360.

    Time frame: 12 Months

  4. Percentage of Participants With Mature Fistula With Preserved Function (MFPF) at 12 Months

    Mature Fistula with Preserved Function at 12 Months (MFPF) defined as a fistula that can be cannulated with 2 needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of ≥300 mL/min (unless the prescribed Qb is \<300 mL/min) performed during any continuous 30-day period that commences no later than 180 days after randomization (i.e., fistula achieves FM) AND can be used for dialysis using 2-needles for at least 75% of the for the dialysis sessions performed during a 30-day period that commences on day 330 (FSD12). MFPF will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The MFPF proportions (and associated 95% CIs) for MFPF for the two groups will be evaluated on day 360.

    Time frame: 12 Months

  5. Percentage of Participants With Durable Fistula Maturation (DFM) at 12 Months

    Durable Fistula Maturation (DFM) defined as a fistula that can be cannulated with 2 needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of ≥300 mL/min performed during any continuous 30-day period that commences no later than 180 days after randomization (i.e., fistula achieves FM) AND can be used for dialysis using 2-needles with a mean Qb of ≥300 mL/min for the dialysis sessions performed during a 30-day period that commences on day 330. DFM will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The DFM proportions (and associated 95% CIs) for DFM for the two groups will be evaluated on day 360.

    Time frame: 12 Months

  6. Cumulative Fistula Use (CFU)

    Cumulative Fistula Use (CFU) defined as the number of dialysis sessions performed using the study fistula with 2 needles and a mean Qb of ≥300 mL/min. CFU is calculated from the time of fistula creation to the end of study period or upon reaching an intercurrent event (Fistula abandonment, Death, Transfer to PD or transplant) or is lost to follow up. CFU was calculated for each participant and then averaged together.

    Time frame: 12 Months

  7. Cumulative Catheter Exposure (CCE)

    Cumulative Catheter Exposure (CCE) is defined as the number of days a hemodialysis central venous catheter (CVC) is in situ and the duration of CVC exposure is calculated from the day of fistula creation (i.e., day of randomization) to the end of study period or upon reaching an intercurrent event. CFU was calculated for each participant and then averaged together.

    Time frame: 12 Months

07

Results

Posted Oct 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment ArmControl Arm
Started6867
Completed5961
Not completed96
Withdrew: Adverse event01
Withdrew: Death74
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage of Participants With Clinical Fistula Maturation (FM)

Clinical Fistula Maturation (FM) is defined as a fistula that can be cannulated with 2-needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of 300 mL/min (unless the prescribed Qb is \<300 mL/min) performed during any continuous 30 day period that commences no later than 180 days after randomization. FM will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The KM proportions (and associated 95% CIs) for FM for the two groups will be evaluated on day 210.

Time frame:
6 Months
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Fistula Maturation (FM)
Percentage of participantsTreatment ArmControl Arm
Percentage of Participants With Clinical Fistula Maturation (FM)69.8 (55.9 to 82.7)65.9 (53 to 78.4)
SecondaryFistula Suitability for Dialysis at 12 Months (FSD12)

Fistula Suitability for Dialysis at 12 months (FSD12) defined as a fistula that can be used for dialysis using 2 needles for at least 75% of the dialysis sessions performed during a 30 day period that commences on day 330.

Time frame:
1 year
Reported as:
Count of participants · Participants
Fistula Suitability for Dialysis at 12 Months (FSD12)
ParticipantsTreatment ArmControl Arm
Fistula Suitability for Dialysis at 12 Months (FSD12)3540
SecondaryPercentage of Participants With Secondary Patency at 12 Months

Secondary Patency (SP) defined as the interval from the time of randomization until access abandonment. SP will be summarized as the cumulative proportion of abandoned AVF by plotting the (inverted SP) Kaplan-Meier (KM) curves for each treatment group and estimating the KM proportions (and associated 95% CIs) of AVF that have maintained SP by day 360 or end of study visit (whichever is later).

Time frame:
12 Months
Reported as:
Number · Percentage of participants
Percentage of Participants With Secondary Patency at 12 Months
Percentage of participantsTreatment ArmControl Arm
Percentage of Participants With Secondary Patency at 12 Months67.3 (54.3 to 77.3)64.8 (44.1 to 79.5)
SecondaryPercentage of Participants With First Dialysis (TTFD) at 12 Months

Time To First Dialysis (TTFD) defined as the interval from the time of randomization to the first of three consecutive dialysis sessions using 2 needles with a mean Qb of ≥300 mL/min (unless the prescribed Qb is \<300 mL/min). TTFD will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for each group (treatment and controls) and estimating the KM proportions (and associated 95% CIs) achieving first dialysis by day 360. TTFD will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The TTFD proportions (and associated 95% CIs) for TTFD for the two groups will be evaluated on day 360.

Time frame:
12 Months
Reported as:
Number · Percentage of participants
Percentage of Participants With First Dialysis (TTFD) at 12 Months
Percentage of participantsTreatment ArmControl Arm
Percentage of Participants With First Dialysis (TTFD) at 12 Months85.7 (72.5 to 94.7)82.2 (70.1 to 91.6)
SecondaryPercentage of Participants With Mature Fistula With Preserved Function (MFPF) at 12 Months

Mature Fistula with Preserved Function at 12 Months (MFPF) defined as a fistula that can be cannulated with 2 needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of ≥300 mL/min (unless the prescribed Qb is \<300 mL/min) performed during any continuous 30-day period that commences no later than 180 days after randomization (i.e., fistula achieves FM) AND can be used for dialysis using 2-needles for at least 75% of the for the dialysis sessions performed during a 30-day period that commences on day 330 (FSD12). MFPF will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The MFPF proportions (and associated 95% CIs) for MFPF for the two groups will be evaluated on day 360.

Time frame:
12 Months
Reported as:
Number · Percentage of participants
Percentage of Participants With Mature Fistula With Preserved Function (MFPF) at 12 Months
Percentage of participantsTreatment ArmControl Arm
Percentage of Participants With Mature Fistula With Preserved Function (MFPF) at 12 Months60.7 (46.8 to 75)60.6 (47.6 to 73.8)
SecondaryPercentage of Participants With Durable Fistula Maturation (DFM) at 12 Months

Durable Fistula Maturation (DFM) defined as a fistula that can be cannulated with 2 needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of ≥300 mL/min performed during any continuous 30-day period that commences no later than 180 days after randomization (i.e., fistula achieves FM) AND can be used for dialysis using 2-needles with a mean Qb of ≥300 mL/min for the dialysis sessions performed during a 30-day period that commences on day 330. DFM will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The DFM proportions (and associated 95% CIs) for DFM for the two groups will be evaluated on day 360.

Time frame:
12 Months
Reported as:
Number · Percentage of participants
Percentage of Participants With Durable Fistula Maturation (DFM) at 12 Months
Percentage of participantsTreatment ArmControl Arm
Percentage of Participants With Durable Fistula Maturation (DFM) at 12 Months52.3 (38.7 to 67.3)41.7 (29.9 to 55.9)
SecondaryCumulative Fistula Use (CFU)

Cumulative Fistula Use (CFU) defined as the number of dialysis sessions performed using the study fistula with 2 needles and a mean Qb of ≥300 mL/min. CFU is calculated from the time of fistula creation to the end of study period or upon reaching an intercurrent event (Fistula abandonment, Death, Transfer to PD or transplant) or is lost to follow up. CFU was calculated for each participant and then averaged together.

Time frame:
12 Months
Reported as:
Mean · Sessions per 1,000 dialysis session days
Cumulative Fistula Use (CFU)
Sessions per 1,000 dialysis session daysTreatment ArmControl Arm
Cumulative Fistula Use (CFU)582 ± 212496 ± 240
SecondaryCumulative Catheter Exposure (CCE)

Cumulative Catheter Exposure (CCE) is defined as the number of days a hemodialysis central venous catheter (CVC) is in situ and the duration of CVC exposure is calculated from the day of fistula creation (i.e., day of randomization) to the end of study period or upon reaching an intercurrent event. CFU was calculated for each participant and then averaged together.

Time frame:
12 Months
Reported as:
Mean · Sessions per 1,000 dialysis session days
Cumulative Catheter Exposure (CCE)
Sessions per 1,000 dialysis session daysTreatment ArmControl Arm
Cumulative Catheter Exposure (CCE)702 ± 328677 ± 317

Adverse events

Collected over From enrollment until end of follow-up, up to 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm7/68 (10.3%)29/68 (42.6%)56/68 (82.4%)
Control Arm4/67 (6%)26/67 (38.8%)62/67 (92.5%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventTreatment ArmControl Arm
HypervolaemiaMetabolism and nutrition disorders2/685/67
Coronary artery diseaseCardiac disorders3/681/67
Atrial fibrillationCardiac disorders0/682/67
Cardiac failure congestiveCardiac disorders2/682/67
DeathGeneral disorders0/682/67
DyspnoeaRespiratory, thoracic and mediastinal disorders1/682/67
Renal transplantSurgical and medical procedures1/682/67
HypertensionVascular disorders1/682/67
HypotensionVascular disorders1/682/67
AnaemiaBlood and lymphatic system disorders2/681/67
Most frequent other events
Showing 10 of 52
Most frequent other events
EventTreatment ArmControl Arm
Arteriovenous fistula site complicationInjury, poisoning and procedural complications43/6848/67
Vascular access site extravasationInjury, poisoning and procedural complications23/6826/67
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications13/689/67
Arteriovenous fistula maturation failureInjury, poisoning and procedural complications8/689/67
Vascular access complicationInjury, poisoning and procedural complications8/689/67
Device related thrombosisGeneral disorders1/684/67
Arteriovenous fistula site haematomaInjury, poisoning and procedural complications2/684/67
Arteriovenous fistula site haemorrhageInjury, poisoning and procedural complications0/683/67
Vascular access site complicationInjury, poisoning and procedural complications0/683/67
Arteriovenous fistula occlusionInjury, poisoning and procedural complications1/682/67

Baseline characteristics

1 subject randomized to the control arm was removed from analysis due to a major protocol deviation, i.e., subject was not on hemodialysis at the time of enrollment.

Age, Continuous
Age, Continuous(Years)Treatment ArmControl ArmTotal
Mean72.6 ± 6.273.0 ± 6.472.8 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)Treatment ArmControl ArmTotal
Female202444
Male484391
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment ArmControl ArmTotal
American Indian or Alaska Native000
Asian527
Native Hawaiian or Other Pacific Islander000
Black or African American191231
White414990
More than one race011
Unknown or Not Reported336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment ArmControl ArmTotal
Hispanic or Latino171835
Not Hispanic or Latino494695
Unknown or Not Reported235
Region of Enrollment
Region of Enrollment(Participants)Treatment ArmControl ArmTotal
United States504999
United Kingdom181836
Duration of hemodialysis
Duration of hemodialysis(Months)Treatment ArmControl ArmTotal
Mean5.29 ± 3.594.78 ± 3.25.04 ± 3.39
08

Study locations

22 sites
  • Veterans Affairs San Diego Health Center
    San Diego, California 92161, United States
  • Lundquist Institute for Biomedical Innovation
    Torrance, California 90502, United States
  • MedStar Cardiovascular Research Network at MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • American Access Care of Miami
    Miami, Florida 33156, United States
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • The Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Atrium Health
    Charlotte, North Carolina 28204, United States
  • Surgical Specialists of Charlotte
    Charlotte, North Carolina 28207, United States
  • The Regional Medical Center/Dialysis Access Institute
    Orangeburg, South Carolina 29118, United States
  • James Eric Gardner, MD PC
    Memphis, Tennessee 38115, United States
  • Arteries & Veins
    El Paso, Texas 79912, United States
  • Houston Methodist
    Houston, Texas 77030, United States
  • Houston Methodist
    Sugar Land, Texas 77479, United States
  • Sentara Norfolk General Hospital/Sentara Health Research Center
    Norfolk, Virginia 23507, United States
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, United Kingdom
  • St Helier Hospital
    Carshalton, SM5 1AA, United Kingdom
  • NHS Greater Glasgow and Clyde
    Glasgow, United Kingdom
  • Barts Health NHS Trust of Royal London Hospital
    London, United Kingdom
  • St George's University Hospitals NHS Foundation Trust
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data (IPD) collected in this study will not be shared.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Mar 2025, 30 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 30 months is close to that.

Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2022
First posted
Jun 21, 2022
StartActual
Aug 26, 2022
Primary completionActual
Mar 18, 2025
CompletionActual
Aug 29, 2025
Results first posted
Oct 6, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercentage of Participants With Clinical Fistula Maturation (FM)Time frame: 6 Months
Oct 6, 2026
Secondary outcomes
5 edited, 2 time frame changed, 2 description edited
What changed in the outcomes
  • EditedFistula Suitability for Dialysis at 12 monthsMonths (FSD12)Time frame: 1 year
  • EditedTime ToPercentage of Participants With First Dialysis (TTFD) at 12 MonthsTime frame: 1 year → 12 Months
  • EditedPercentage of Participants With Mature Fistula withWith Preserved Function (MFPF) at 12 Months (MFPF)Time frame: 1 year → 12 Months
  • EditedPercentage of Participants With Durable Fistula Maturation (DFM) at 12 MonthsTime frame: 1 year → 12 Months
  • ChangedBefore Secondary Patency (SP)Now Percentage of Participants With Secondary Patency at 12 MonthsTime frame: 1 year → 12 Months
  • Time frameCumulative Fistula Use (CFU)1 year → 12 Months
  • Time frameCumulative Catheter Exposure (CCE)1 year → 12 Months
  • DescriptionCumulative Catheter Exposure (CCE): how it is measured was reworded
  • DescriptionCumulative Fistula Use (CFU): how it is measured was reworded
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercentage of Participants With Clinical Fistula Maturation (FM)Time frame: 6 Months
    Secondary outcomes 5 edited, 2 time frame changed, 2 description edited
    What changed in the outcomes
    • EditedFistula Suitability for Dialysis at 12 monthsMonths (FSD12)Time frame: 1 year
    • EditedTime ToPercentage of Participants With First Dialysis (TTFD) at 12 MonthsTime frame: 1 year → 12 Months
    • EditedPercentage of Participants With Mature Fistula withWith Preserved Function (MFPF) at 12 Months (MFPF)Time frame: 1 year → 12 Months
    • EditedPercentage of Participants With Durable Fistula Maturation (DFM) at 12 MonthsTime frame: 1 year → 12 Months
    • ChangedBefore Secondary Patency (SP)Now Percentage of Participants With Secondary Patency at 12 MonthsTime frame: 1 year → 12 Months
    • Time frameCumulative Fistula Use (CFU)1 year → 12 Months
    • Time frameCumulative Catheter Exposure (CCE)1 year → 12 Months
    • DescriptionCumulative Catheter Exposure (CCE): how it is measured was reworded
    • DescriptionCumulative Fistula Use (CFU): how it is measured was reworded
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05425056
Lead sponsor
Vascular Therapies, Inc.
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Aug 26, 2022
Primary completion
Mar 18, 2025
Completion
Aug 29, 2025
Results posted
Oct 6, 2026
Last update
Oct 6, 2026

Study contacts

Sriram Iyer, MD
study director · Vascular Therapies, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion